Company Profile
Cognition Therapeutics Stock Price, News & Analysis
- Ticker:
- CGTX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.13 USD (+6.60%)
Close
Last updated: August 6, 2026
121M USD
Market cap
Why the stock is moving
The latest monitored company update is “Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update.” The corresponding closing-price reaction is not yet available.
Company overview
Neurodegenerative-Disease Development
Cognition Therapeutics develops small-molecule therapies for neurodegenerative disorders. Its work focuses on synaptic dysfunction and toxic protein biology associated with dementia.
Zervimesine
Zervimesine is an oral sigma-2 receptor modulator being studied in dementia with Lewy bodies and Alzheimer's disease. The candidate is intended to protect neuronal function by regulating cellular pathways involved in protein trafficking and stress.
Dual Clinical Strategy
The company is pursuing a registrational path in dementia with Lewy bodies psychosis while continuing a large Phase 2 program in mild cognitive impairment and early Alzheimer's disease.
Future catalysts
FDA meeting in May 2026 to inform registrational plans for zervimesine in dementia with Lewy bodies psychosis.
Topline results from the Phase 2 START study of zervimesine in 2027.
Recent news
- 01
Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update
Source: Cognition Therapeutics
- 02
Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit
Source: Cognition Therapeutics
- 03
- 04
- 05
Cognition Therapeutics Participating in Upcoming Investor Conferences
Source: Cognition Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Cognition Therapeutics (CGTX)?
Cognition Therapeutics (CGTX) most recently closed at 1.13 USD, a +6.60% move versus the previous session.
What is the market cap of Cognition Therapeutics (CGTX)?
Cognition Therapeutics currently has a market capitalization of 121M USD on BioPharmSignal.
What does Cognition Therapeutics do?
Neurodegenerative-Disease Development Cognition Therapeutics develops small-molecule therapies for neurodegenerative disorders. Its work focuses on synaptic dysfunction and toxic protein biology associated with dementia. Zervimesine Zervimesine is an oral sigma-2 receptor modulator being studied in dementia with Lewy bodies and Alzheimer's disease. The...
On which exchange is CGTX stock listed?
Cognition Therapeutics (CGTX) is associated with NASDAQ, United States, Biopharma.
What is Neurodegenerative-Disease?
Neurodegenerative-Disease Development Cognition Therapeutics develops small-molecule therapies for neurodegenerative disorders.
Which conditions is Cognition Therapeutics targeting with Neurodegenerative-Disease?
Neurodegenerative-Disease Development Cognition Therapeutics develops small-molecule therapies for neurodegenerative disorders. Its work focuses on synaptic dysfunction and toxic protein biology associated with dementia. Zervimesine Zervimesine is an oral sigma-2 receptor modulator being studied in dementia with Lewy bodies and Alzheimer's disease. The...
How does Cognition Therapeutics describe recent progress with Neurodegenerative-Disease?
FDA meeting in May 2026 to inform registrational plans for zervimesine in dementia with Lewy bodies psychosis. Topline results from the Phase 2 START study of zervimesine in 2027.
What is Development?
Neurodegenerative-Disease Development Cognition Therapeutics develops small-molecule therapies for neurodegenerative disorders.